01 Oct New HPV Vaccine Has Potential To Prevent Nearly All Cervical Pre-Cancers
MedicalResearch.com Interview with:
Elmar A. Joura, MD
Department of Gynaecology and Obstetrics
Medical University of Vienna, Comprehensive Cancer Center
Vienna, Austria
Medical Research: What are the main findings of the study?
Dr. Joura: The upcoming ninevalent vaccine has the potential to prevent 85% of the cervical precancers and surgeries such as LEEP (conization)
Medical Research: What was most surprising about the results?
Dr. Joura: In coinfections we got the same result with various mathematical models: high grade disease will be effectively prevented, since these 9 types are the most prevalent strains, in single AND in co-infections
Medical Research: What should clinicians and patients take away from your report?
Dr. Joura: With the currently available vaccines we achieve an excellent protection, but this level of protection will be even better in the future. The key thing is that the coverage for HPV vaccination has to improve in the future.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. Joura: After this modeling and the randomized phase III trials, we need results in a real life situation and long term follow up. this research has to be extended to other HPV related diseases, other age groups and males.
Citation:
Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease
Cancer Epidemiol Biomarkers Prev October 2014 23:1997-2008; doi:10.1158/1055-9965.EPI-14-0410
Last Updated on October 1, 2014 by Marie Benz MD FAAD